Conference Coverage
11/05/2026
Rebecca Amrick
A study presented at AASLD TLM 2026 found that a PharmD-led sub-clinic improved access to semaglutide and facilitated timely treatment initiation among patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
A study presented at AASLD TLM 2026 found that a PharmD-led sub-clinic improved access to semaglutide and facilitated timely treatment initiation among patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
A study presented at AASLD TLM...
11/05/2026
First Report Managed Care
